Effects of Alsava on renal ischemia-reperfusion injury in rats

Abstract

Kidney ischemia-reperfusion injury (IRI) is a leading cause of acute kidney injury (AKI) occurring frequently under major surgeries and sepsis. This study aimed to evaluate the effect of Edaravone (Alsava), an FDA-approved free radical scavenger, on the kidney IRI rat model. Material and methods. Male Wistar rats (n= 24) were allocated into (i) Sham, (ii) EDA, (iii) ischemia/reperfusion (I/R), and (IV) EDA+ I/R groups. Animals in the last two groups received one-dosage Edaravone (100 mg/kg) 1h before I/R via intraperitoneal injection. To examine the effect of EDA on antioxidant molecules, the activity of catalase (CAT), glutathione peroxidase (GPx), and levels of glutathione (GSH) and total antioxidant capacity (TAC) in the kidney were evaluated. Moreover, to evaluate lipid peroxidation, the levels of malondialdehyde (MDA), a marker of oxidative stress, were examined. Results. Compared with the sham group, a significant decrease was observed in the GPX, CAT, and SOD enzyme activities and GSH and TAC levels in the I/R groups (P<0.05). Administration of EDA could significantly enhance the TAC, GSH levels as well as GPX, and SOD activities were detected in the EDA+ I/R group, in comparison to the I/R group (P <0.05). However, EDA could not decrease MDA levels significantly in IR-induced AKI rats compared to the I/R group.